Polymorphisms in NQO1 and MPO genes and risk for bladder cancer in Tunisian population.
NQO1 and MPO polymorphism
RFLP
benzene
bladder cancer
smoking
Journal
Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
08
09
2021
received:
11
05
2021
accepted:
09
09
2021
pubmed:
23
9
2021
medline:
5
4
2022
entrez:
22
9
2021
Statut:
ppublish
Résumé
NAD (P) H: quinone oxidoreductase (1) (NQO1-HGNC: 2874) and myeloperoxidase (MPO-HGNC: 7218) are two enzymes involved in phase II of the xenobiotic metabolism pathway. In this study, a case-control analysis was conducted to investigate the relationship between genetic variations in the NQO1 (C609T, rs1800566; IVS1-27 C >G, rs689452) and MPO (G463A, rs2333227) genes and the risk for bladder cancer among Tunisian population. We have found that the MPO 463GA genotype was associated with a decreased risk of developing bladder cancer (p = 0.049; OR = 0.696; 95% CI 0.484-0.999). In contrast, we have found that the NQO1 609CT genotype could increase the risk of bladder cancer patients (p = 0.0039; OR = 1.454; 95% CI = 1.017-2.078). Moreover, patients with "NQO1 609 CT/IVS1-27 CG" genotype show a 2.180-fold increasing risk for developing bladder cancer in comparison to the control group with wild genotype. This OR is estimated at 5.6-fold in smokers patients with "NQO1 609 CT/IVS1-27 CG" genotype. Lastly, study findings suggest that the NQO1 IVS-27 *CG genotype (rs689452) is associated with a risk of progression to muscle invasive bladder cancer. Our study suggests that environmental risk factors in association to NQO1 genotypes (NQO1 609 CT/IVS1-27 CG) play an important role in the development of bladder cancer in Tunisian population.
Sections du résumé
BACKGROUND
NAD (P) H: quinone oxidoreductase (1) (NQO1-HGNC: 2874) and myeloperoxidase (MPO-HGNC: 7218) are two enzymes involved in phase II of the xenobiotic metabolism pathway.
METHODS
In this study, a case-control analysis was conducted to investigate the relationship between genetic variations in the NQO1 (C609T, rs1800566; IVS1-27 C >G, rs689452) and MPO (G463A, rs2333227) genes and the risk for bladder cancer among Tunisian population.
RESULTS
We have found that the MPO 463GA genotype was associated with a decreased risk of developing bladder cancer (p = 0.049; OR = 0.696; 95% CI 0.484-0.999). In contrast, we have found that the NQO1 609CT genotype could increase the risk of bladder cancer patients (p = 0.0039; OR = 1.454; 95% CI = 1.017-2.078). Moreover, patients with "NQO1 609 CT/IVS1-27 CG" genotype show a 2.180-fold increasing risk for developing bladder cancer in comparison to the control group with wild genotype. This OR is estimated at 5.6-fold in smokers patients with "NQO1 609 CT/IVS1-27 CG" genotype. Lastly, study findings suggest that the NQO1 IVS-27 *CG genotype (rs689452) is associated with a risk of progression to muscle invasive bladder cancer.
CONCLUSION
Our study suggests that environmental risk factors in association to NQO1 genotypes (NQO1 609 CT/IVS1-27 CG) play an important role in the development of bladder cancer in Tunisian population.
Identifiants
pubmed: 34549902
doi: 10.1002/mgg3.1819
pmc: PMC8606214
doi:
Substances chimiques
NAD(P)H Dehydrogenase (Quinone)
EC 1.6.5.2
NQO1 protein, human
EC 1.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1819Informations de copyright
© 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.
Références
J Occup Environ Med. 2016 Aug;58(8):e301-7
pubmed: 27294445
BMC Med Genet. 2013 Mar 05;14:31
pubmed: 23497461
BMC Res Notes. 2010 Jul 27;3:212
pubmed: 20663217
Sci Total Environ. 2007 Mar 15;374(2-3):183-98
pubmed: 17261327
Int J Mol Epidemiol Genet. 2013 Nov 28;4(4):207-17
pubmed: 24319536
Pharmacogenetics. 1997 Jun;7(3):235-9
pubmed: 9241663
Int J Environ Res Public Health. 2011 Feb;8(2):613-28
pubmed: 21556207
Curr Opin Urol. 2014 Sep;24(5):492-9
pubmed: 24887046
Br J Cancer. 2013 Sep 3;109(5):1325-37
pubmed: 23860519
Genet Med. 2005 Sep;7(7):463-78
pubmed: 16170238
Environ Health. 2012 Jun 28;11 Suppl 1:S11
pubmed: 22759493
Anticancer Res. 2007 Nov-Dec;27(6B):4107-10
pubmed: 18225579
Cancer Res. 1992 Feb 15;52(4):797-802
pubmed: 1737339
Mol Genet Genomic Med. 2021 Nov;9(11):e1819
pubmed: 34549902
Am J Ind Med. 2002 Jul;42(1):29-37
pubmed: 12111688
J Korean Med Sci. 2015 Mar;30(3):221-6
pubmed: 25729241
J Med Dent Sci. 2010 Jun;57(2):139-45
pubmed: 21073132
Can Urol Assoc J. 2009 Dec;3(6 Suppl 4):S193-8
pubmed: 20019984
Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1501-8
pubmed: 14693744
Cancer Res. 2003 Dec 1;63(23):8108-12
pubmed: 14678961
Cancer Inform. 2016 Apr 10;14(Suppl 5):87-107
pubmed: 27081306
Carcinogenesis. 2008 Oct;29(10):1955-62
pubmed: 18632753
Biomark Med. 2016;10(2):145-63
pubmed: 26764284
Arch Med Sci. 2014 Aug 29;10(4):651-60
pubmed: 25276147
Genet Med. 2002 Mar-Apr;4(2):62-70
pubmed: 11882782
Carcinogenesis. 2001 Mar;22(3):367-74
pubmed: 11238174
Environ Health Perspect. 1996 Dec;104 Suppl 6:1129-36
pubmed: 9118882
Chem Biol Interact. 2000 Dec 1;129(1-2):77-97
pubmed: 11154736
JAMA. 2011 Aug 17;306(7):737-45
pubmed: 21846855
Hum Mutat. 2000;15(1):105-13
pubmed: 10612830
J Biol Chem. 1996 Jun 14;271(24):14412-20
pubmed: 8662930
Am J Epidemiol. 2008 Dec 1;168(11):1221-32
pubmed: 18945694
Clin Cancer Res. 2005 Aug 1;11(15):5444-50
pubmed: 16061860
Cancer Res. 2004 Sep 1;64(17):5925-8
pubmed: 15342368
Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8413-7
pubmed: 8078896
Blood. 1999 Jul 15;94(2):803-7
pubmed: 10397748
Cancer Invest. 2015 Mar;33(2):39-40
pubmed: 25608636
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593